Start for free
Start for free
Shire logo

Shire

Europe, Dublin, Ireland, Dublin

Description

Shire biotechnology company that focuses on serving people with rare diseases.

Investor Profile

Shire has made 12 investments, with 0 in the past 12 months and 17% as lead.

Stage Focus

  • Series B (33%)
  • Series C (25%)
  • Series A (17%)
  • Series D (17%)
  • Series Unknown (8%)

Country Focus

  • United States (75%)
  • Belgium (17%)
  • France (8%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Health Care
  • Life Science
  • Biopharma
  • Pharmaceutical
  • Medical
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Shire frequently co-invest with?

FV
Fibrotic Ventures
North America, Georgia, United States, Atlanta
Co-Investments: 1
Omnes Capital
Omnes Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 1
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund
Europe, Rheinland-Pfalz, Germany, Ingelheim Am Rhein
Co-Investments: 2
Mitsui Global Investment
Mitsui Global Investment
North America, California, United States, Menlo Park
Co-Investments: 2
Lundbeckfonden Ventures
Lundbeckfonden Ventures
Europe, Hovedstaden, Denmark, Copenhagen
Co-Investments: 1
Seventure Partners
Seventure Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 1
HealthCare Ventures
HealthCare Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Forbion Capital Partners
Forbion Capital Partners
Europe, Noord-Holland, The Netherlands, Naarden
Co-Investments: 1
Easton Capital
Easton Capital
North America, New York, United States, New York
Co-Investments: 1
Mérieux Equity Partners
Mérieux Equity Partners
Europe, Rhone-Alpes, France, Lyon
Co-Investments: 4

What are some of recent deals done by Shire?

Rani Therapeutics

San Jose, California, United States

Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.

BiotechnologyPharmaceuticalTherapeutics
Series UnknownFeb 7, 2018
Amount Raised: $53,000,000
Promethera Biosciences

Mont-saint-guibert, Brabant Wallon, Belgium

Promethera Biosciences is a biopharmaceutical company focused on cell therapy products to treat liver diseases.

BiotechnologyPharmaceuticalTherapeutics
Series CNov 25, 2014
Amount Raised: $31,559,553
Naurex

Evanston, Illinois, United States

Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.

BiopharmaBiotechnologyTherapeutics
Series CMay 6, 2014
Amount Raised: $25,000,000
Proclara Biosciences

Cambridge, Massachusetts, United States

Proclara is pioneering a new approach to treating neurodegenerative diseases.

BiotechnologyHealth CareLife ScienceTherapeutics
Series DMar 25, 2014
Amount Raised: $17,000,000
Proclara Biosciences

Cambridge, Massachusetts, United States

Proclara is pioneering a new approach to treating neurodegenerative diseases.

BiotechnologyHealth CareLife ScienceTherapeutics
Series CMay 6, 2013
Amount Raised: $6,400,000
ArmaGen Technologies

Santa Monica, California, United States

ArmaGen is focused on developing technologies for siRNA delivery across the blood-brain barrier.

BiotechnologyHealth CareMedical
Series ANov 29, 2012
Amount Raised: $17,000,000
Promedior

Lexington, Massachusetts, United States

Promedior is a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases.

BiopharmaBiotechnologyHealth CareTherapeutics
Series DOct 15, 2012
Amount Raised: $3,000,000
Promethera Biosciences

Mont-saint-guibert, Brabant Wallon, Belgium

Promethera Biosciences is a biopharmaceutical company focused on cell therapy products to treat liver diseases.

BiotechnologyPharmaceuticalTherapeutics
Series BMar 28, 2012
Amount Raised: $31,432,175
ENTEROME

Paris, Ile-de-France, France

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

BiopharmaBiotechnologyHealth CareLife Science
Series AMar 23, 2012
Amount Raised: $9,945,367
Proclara Biosciences

Cambridge, Massachusetts, United States

Proclara is pioneering a new approach to treating neurodegenerative diseases.

BiotechnologyHealth CareLife ScienceTherapeutics
Series BMar 8, 2012
Amount Raised: $9,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator